Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, proudly announces the launch of Biozen Native RP-1 and RP-5. As Antibody-Drug Conjugates (ADCs) continue to emerge as a pivotal approach in targeted cancer therapeutics, the demand for precise and efficient characterization methods is increasing.
Native RP-1, developed in tandem with Native RP-5, is an advanced chromatography column designed to revolutionize ADC Drug to Antibody Ratio (DAR) analysis through orthogonal reversed-phase separation under native conditions, facilitating direct mass spectrometry (MS) detection. While traditional HIC methods offer reproducibility, they are hindered by long method times and high salt mobile phases that are incompatible with MS detection. Native reversed-phase analysis overcomes these challenges, providing comprehensive information essential for the development and consistent therapeutic performance of ADC therapeutics.
- Reduce Sample Manipulation: Eliminate fractionation and buffer exchange steps to reduce sample manipulation by 75 % compared to traditional methods.
- Reproducible and Efficient: Achieve consistent resolution of DAR isoforms and reduce the number of ADC characterization methods by one-third.
- Enhanced Throughput: Improve high-quality data to streamline critical throughput screening decisions
Read the Entire Press Release Here
